NO20032437L - Fremgangsmåte for krystallisering av (R)- eller (S)- lansoprazol - Google Patents

Fremgangsmåte for krystallisering av (R)- eller (S)- lansoprazol

Info

Publication number
NO20032437L
NO20032437L NO20032437A NO20032437A NO20032437L NO 20032437 L NO20032437 L NO 20032437L NO 20032437 A NO20032437 A NO 20032437A NO 20032437 A NO20032437 A NO 20032437A NO 20032437 L NO20032437 L NO 20032437L
Authority
NO
Norway
Prior art keywords
lansoprazole
crystal
crystallizing
production method
present
Prior art date
Application number
NO20032437A
Other languages
English (en)
Other versions
NO326019B1 (no
NO20032437D0 (no
Inventor
Hideo Hashimoto
Tadashi Urai
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18838123&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20032437(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO20032437D0 publication Critical patent/NO20032437D0/no
Publication of NO20032437L publication Critical patent/NO20032437L/no
Publication of NO326019B1 publication Critical patent/NO326019B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20032437A 2000-12-01 2003-05-28 Fremgangsmate for fremstilling av (R)- eller (S)-lansoprazol og anvendelse av de fremstilte krystaller NO326019B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367757 2000-12-01
PCT/JP2001/010462 WO2002044167A1 (en) 2000-12-01 2001-11-30 Process for the crystallization of (r)- or (s)-lansoprazole

Publications (3)

Publication Number Publication Date
NO20032437D0 NO20032437D0 (no) 2003-05-28
NO20032437L true NO20032437L (no) 2003-07-17
NO326019B1 NO326019B1 (no) 2008-09-01

Family

ID=18838123

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032437A NO326019B1 (no) 2000-12-01 2003-05-28 Fremgangsmate for fremstilling av (R)- eller (S)-lansoprazol og anvendelse av de fremstilte krystaller

Country Status (17)

Country Link
US (2) US7285668B2 (no)
EP (2) EP2345650A1 (no)
KR (3) KR20100002278A (no)
CN (1) CN1254473C (no)
AT (1) ATE511508T1 (no)
AU (1) AU2002218506A1 (no)
CA (1) CA2436825C (no)
CY (1) CY1112347T1 (no)
DK (1) DK1337525T3 (no)
ES (1) ES2367419T3 (no)
HK (1) HK1054380B (no)
HU (1) HU229356B1 (no)
NO (1) NO326019B1 (no)
PL (3) PL214684B1 (no)
PT (1) PT1337525E (no)
TW (1) TWI290922B (no)
WO (1) WO2002044167A1 (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020027315A1 (en) * 2000-03-10 2002-03-07 Parker Gerard E. Low-firing temperature method for producing Al2O3 bodies having enhanced chemical resistance
EP1293507B1 (en) * 2000-05-15 2007-11-28 Takeda Pharmaceutical Company Limited Process for producing crystal
AU2003224779A1 (en) * 2002-03-27 2003-10-13 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
EP1552833B1 (en) * 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
AU2004207720A1 (en) * 2003-01-31 2004-08-12 Teijin Pharma Limited Crystal of (23S)-1alpha-hydroxy-27-nor-25-methylenevitamin D3-26,23-lactone and process for producing the same
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
JP2006528182A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 薬学的製剤および酸に起因する消化器疾患の治療法
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2006528181A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
JP2007522217A (ja) * 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
EP1681056A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
WO2007074909A1 (ja) 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited 放出制御固形製剤
KR100758600B1 (ko) * 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
JP5366558B2 (ja) 2006-12-28 2013-12-11 武田薬品工業株式会社 口腔内崩壊性固形製剤
WO2008087665A2 (en) * 2007-01-18 2008-07-24 Matrix Laboratories Ltd Process for preparation of lansoprazole
KR101303813B1 (ko) 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
CN102014638A (zh) * 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
EP2222663A1 (en) * 2007-12-18 2010-09-01 Watson Pharma Private Limited A process for preparation of stable amorphous r-lansoprazole
AU2009224247B2 (en) 2008-03-10 2013-12-12 Takeda Pharmaceutical Company Limited Crystal of benzimidazole compound
BRPI0912478A2 (pt) 2008-05-14 2016-02-10 Watson Pharma Private Ltd sal de r-(+)-lansoprazol alquilamina, processo para preparar um sal de r-(+)-lansoprazol alquilamina estável e forma de dosagem farmacêutica
US20100113527A1 (en) * 2008-09-30 2010-05-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
WO2010056059A2 (en) * 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
IT1391776B1 (it) * 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
WO2010095144A2 (en) * 2009-02-04 2010-08-26 Msn Laboratories Limited Process for the preparation of proton pump inhibitors
IT1392813B1 (it) * 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) * 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
WO2011092665A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
US9085556B2 (en) 2010-03-31 2015-07-21 Ranbaxy Laboraotories Limited Salts of dexlansoprazole and their preparation
CA2795110C (en) * 2010-03-31 2015-06-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
US20130216617A1 (en) 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
WO2012074110A1 (ja) 2010-12-03 2012-06-07 武田薬品工業株式会社 口腔内崩壊錠
US20130273157A1 (en) 2010-12-27 2013-10-17 Takeda Pharmaceutical Company Limited Orally disintegrating tablet
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
EP2723728A1 (en) 2011-06-21 2014-04-30 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
CA2857457C (en) 2011-11-30 2018-05-01 Takeda Pharmaceutical Company Limited Dry coated tablet
EP2798842A4 (en) 2011-12-29 2015-12-09 Intel Corp COMPRESSION WITH VARIABLE DEPTH
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
SG11201509439SA (en) 2013-05-21 2015-12-30 Takeda Pharmaceutical Orally disintegrable tablet
CN103254174B (zh) * 2013-06-05 2014-06-11 湖北济生医药有限公司 一种兰索拉唑化合物及其药物组合物
CN105339399B (zh) 2013-06-20 2018-01-02 日本聚丙烯株式会社 丙烯系嵌段共聚物
CN104958276A (zh) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物兰索拉唑组合物胶囊
CN104997739A (zh) * 2015-08-31 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物兰索拉唑组合物冻干粉针剂
CN105399728B (zh) * 2015-12-20 2017-11-28 寿光富康制药有限公司 一种适用于工业化生产的右兰索拉唑的处理方法
CN106279107A (zh) * 2016-08-10 2017-01-04 成都尚药科技有限公司 一种右旋兰索拉唑晶型的制备方法
CN106749182A (zh) * 2016-11-08 2017-05-31 山东裕欣药业有限公司 一种右旋兰索拉唑晶型化合物及其制备方法
IT201700050223A1 (it) 2017-05-09 2018-11-09 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
JPH1085502A (ja) * 1996-09-19 1998-04-07 Konica Corp 晶析方法
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
TR199901101T2 (xx) * 1996-11-22 1999-07-21 The Procter & Gamble Company Gastroenstentinal hastal�klar�n tedavisine y�nelik bizmut ve nsaid i�eren bile�imler.
AU2481899A (en) * 1998-01-30 1999-08-16 Sepracor, Inc. S-lansoprazole compositions and methods
JP4536905B2 (ja) * 1999-06-17 2010-09-01 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
AU5705700A (en) * 1999-06-30 2001-01-22 Takeda Chemical Industries Ltd. Crystals of benzimidazole compounds
JP2001039975A (ja) * 1999-07-26 2001-02-13 Eisai Co Ltd スルホキシド誘導体の結晶およびその製造法
WO2001014366A1 (en) 1999-08-25 2001-03-01 Takeda Chemical Industries, Ltd. Process for the preparation of optically active sulfoxide derivatives
CN1193024C (zh) 2000-04-28 2005-03-16 武田药品工业株式会社 生产旋光的亚砜衍生物的方法
EP1293507B1 (en) 2000-05-15 2007-11-28 Takeda Pharmaceutical Company Limited Process for producing crystal
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法

Also Published As

Publication number Publication date
HK1054380A1 (en) 2003-11-28
CN1478086A (zh) 2004-02-25
CA2436825C (en) 2011-01-18
DK1337525T3 (da) 2011-09-19
PL399787A1 (pl) 2012-11-05
KR20030060967A (ko) 2003-07-16
EP1337525A1 (en) 2003-08-27
ATE511508T1 (de) 2011-06-15
KR100887912B1 (ko) 2009-03-12
CA2436825A1 (en) 2002-06-06
US20040049045A1 (en) 2004-03-11
KR20090003348A (ko) 2009-01-09
PL409463A1 (pl) 2016-02-15
NO326019B1 (no) 2008-09-01
WO2002044167A1 (en) 2002-06-06
PL362801A1 (en) 2004-11-02
HUP0400781A2 (hu) 2004-07-28
PL214684B1 (pl) 2013-09-30
HU229356B1 (en) 2013-11-28
ES2367419T3 (es) 2011-11-03
HUP0400781A3 (en) 2010-03-29
TWI290922B (en) 2007-12-11
CN1254473C (zh) 2006-05-03
EP1337525B1 (en) 2011-06-01
CY1112347T1 (el) 2015-12-09
EP1337525B8 (en) 2011-10-05
NO20032437D0 (no) 2003-05-28
EP2345650A1 (en) 2011-07-20
KR20100002278A (ko) 2010-01-06
HK1054380B (en) 2012-01-27
AU2002218506A1 (en) 2002-06-11
KR100939948B1 (ko) 2010-02-04
PT1337525E (pt) 2011-09-01
US20080306118A1 (en) 2008-12-11
US7285668B2 (en) 2007-10-23

Similar Documents

Publication Publication Date Title
NO20032437D0 (no) Fremgangsmåte for krystallisering av (R)- eller (S)- lansoprazol
DK0573848T3 (da) Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
DE60235089D1 (de) Verfahren zur stabilisierung von reduziertem coenzym q10 und verfahren zur sauren kristallisation
DE60105113D1 (de) Verfahren zur Herstellung von einem Kristallepoxid
DE69327567D1 (de) Verfahren zur Herstellung von Alanylglutamin
DE69004101D1 (de) Verfahren zur kristallisation von enzymen.
KR870004498A (ko) 실리콘 기판의 제법
DE602004004095D1 (de) Tiegel für eine vorrichtung zur herstellung eines kristallinen blockes, und verfahren zu seiner herstellung
NO20005660L (no) Nye mellomprodukter og fremgangsmåter for fremstilling av optisk aktive oktansyrederivater
RU95107144A (ru) Стабильная кристаллическая (6s)- и (6r)-тетрагидрофолиевая кислота
DE68916174D1 (de) Mevalonolactone vom Thienopyridin-Typ.
DE60316791D1 (de) Verfahren zur aufreinigung von lanzoprazol
BR9913720A (pt) Processo de purificação por cristalização ourecristalização de ácidos carboxìlicos
MA19258A1 (fr) Procede de separation selective de cobalt (ii) de solutions aqueuses .
CY1109545T1 (el) Συνθεση της (r) και (s)-αμινοκαρνιτινης και παραγωγων που προκυπτουν απο to d- και l- ασπαρτικο οξυ
DK0782996T3 (da) Fremgangsmåde til fremstilling af N-biphenylmethylthiadiazolinderivat eller salt deraf og mellemprodukt til fremstilling af
DK0811603T3 (da) Aminotetralonderivater og fremgangsmåder til fremstilling af samme
ATE88999T1 (de) Reinigung von isothiazolonen.
DE60019723D1 (de) Eine methode zur herstellung von verbindungen der formel 1 und derivaten
DE60011739D1 (de) Kristallines oder kristallisiertes Säureadditionssalz von Losartan und Verfahren zur Reinigung von Losartan
ATE307140T1 (de) Kristallisierung von alpha-l-aspartyl-l- phenylalaninmethylester aus übersättigten lösungen
UA27812C2 (uk) Спосіб одержання кристалічної моногідратної форми лоракарбефа
DE60233541D1 (de) Verfahren zur Reinigung von 5'-geschützten 2'-Deoxypurin Nukleosiden
DE602004028230D1 (de) Verfahren zur Reinigung und zur Herstellung von Phosphorsäure
DE60123213D1 (de) Alkalimetallsalz von thiazolidin-2,4-dion-derivaten

Legal Events

Date Code Title Description
MK1K Patent expired